JPWO2023064850A5 - - Google Patents
Info
- Publication number
- JPWO2023064850A5 JPWO2023064850A5 JP2024522207A JP2024522207A JPWO2023064850A5 JP WO2023064850 A5 JPWO2023064850 A5 JP WO2023064850A5 JP 2024522207 A JP2024522207 A JP 2024522207A JP 2024522207 A JP2024522207 A JP 2024522207A JP WO2023064850 A5 JPWO2023064850 A5 JP WO2023064850A5
- Authority
- JP
- Japan
- Prior art keywords
- erap1
- complement
- seq
- nucleic acid
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163255597P | 2021-10-14 | 2021-10-14 | |
| US63/255,597 | 2021-10-14 | ||
| US202263328008P | 2022-04-06 | 2022-04-06 | |
| US63/328,008 | 2022-04-06 | ||
| PCT/US2022/078037 WO2023064850A1 (en) | 2021-10-14 | 2022-10-13 | Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (erap1) inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024536491A JP2024536491A (ja) | 2024-10-04 |
| JPWO2023064850A5 true JPWO2023064850A5 (https=) | 2025-09-05 |
| JP2024536491A5 JP2024536491A5 (https=) | 2025-09-05 |
Family
ID=84332068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024522207A Pending JP2024536491A (ja) | 2021-10-14 | 2022-10-13 | 小胞体アミノペプチダーゼ１（ｅｒａｐ１）阻害剤によるぶどう膜炎の治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US12157891B2 (https=) |
| EP (1) | EP4416286A1 (https=) |
| JP (1) | JP2024536491A (https=) |
| MX (1) | MX2024004558A (https=) |
| WO (1) | WO2023064850A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8968731B2 (en) * | 2009-10-09 | 2015-03-03 | Csl Limited | Treatment of uveitis |
| US20130315933A1 (en) * | 2010-10-06 | 2013-11-28 | Christoph Renner | Antibodies Directed Against HLA-B27 Homodimers and Methods and Uses Thereof in Diagnosis and Therapy |
| TWI619729B (zh) * | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
| WO2014155278A2 (en) * | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
| EP4058429A1 (en) | 2019-11-14 | 2022-09-21 | Grey Wolf Therapeutics Limited | Erap1 modulators |
| AU2021316196B2 (en) | 2020-07-25 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Modulation of endoplasmic reticulum aminopeptidase 2 (ERAP2)-mediated immune response |
-
2022
- 2022-10-13 US US18/046,291 patent/US12157891B2/en active Active
- 2022-10-13 JP JP2024522207A patent/JP2024536491A/ja active Pending
- 2022-10-13 WO PCT/US2022/078037 patent/WO2023064850A1/en not_active Ceased
- 2022-10-13 MX MX2024004558A patent/MX2024004558A/es unknown
- 2022-10-13 EP EP22802441.0A patent/EP4416286A1/en active Pending
-
2024
- 2024-10-24 US US18/925,493 patent/US20250115918A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190062740A1 (en) | COMPOSITIONS AND METHODS OF USING piRNAS IN CANCER DIAGNOSTICS AND THERAPEUTICS | |
| JP2023531935A (ja) | Ｇタンパク質共役受容体７５（ｇｐｒ７５）阻害剤による肥満の治療 | |
| JP2017529082A (ja) | ハンチントン病ハプロタイプのための対立遺伝子特異的な療法 | |
| JPWO2019212899A5 (https=) | ||
| Lutz et al. | Epigenetic regulation of the kappa opioid receptor gene by an insertion–deletion in the promoter region | |
| JPWO2023064850A5 (https=) | ||
| Larsen et al. | Conservation of A-to-I RNA editing in bowhead whale and pig | |
| JP2023539742A (ja) | Ｐｃｓｋ９調節物質及びｌｄｌｒ調節物質による敗血症の治療 | |
| US20240182973A1 (en) | Treatment Of Obesity In Subjects Having Variant Nucleic Acid Molecules Encoding Calcitonin Receptor (CALCR) | |
| CN116889627A (zh) | 用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高 | |
| US20220233569A1 (en) | Methods Of Improving Health With Apolipoprotein E (APOE) Inhibitors | |
| CN117255694A (zh) | 用磷酸二酯酶3b(pde3b)抑制剂治疗肝病的方法 | |
| JP2024521754A5 (https=) | ||
| JPWO2021262601A5 (https=) | ||
| CN118541481A (zh) | 用分化簇109(cd109)抑制剂治疗骨矿物质密度降低的方法 | |
| JPWO2023056295A5 (https=) | ||
| Ghazalah et al. | Genetic study of I kappa B alpha gene promoter polymorphism associated with hepatitis C virus in Egyptian patients | |
| US20260027178A1 (en) | Treatment Of Parkinson's Disease With SIM BHLH Transcription Factor 2 (SIM2) Agonists | |
| CN118265529A (zh) | 使用camp应答元件结合蛋白3样3(creb3l3)抑制剂的肝病治疗 | |
| JPWO2023034761A5 (https=) | ||
| RU2023131494A (ru) | Лечение цереброваскулярного заболевания с помощью агентов - белков-гомологов 3 нейрогенного локуса notch (notch3) | |
| Chandler et al. | Single-Cell Transcriptomics Reveals Disrupted Cell Communication in the Glomerular Niche in the Initiation of Childhood WT1 Glomerulopathy: FR-PO310 | |
| CN117940565A (zh) | 用Wnt家族成员5B(WNT5B)抑制剂治疗骨矿物质密度降低 | |
| CN117597132A (zh) | 用环指蛋白213(rnf213)抑制剂治疗肝病 | |
| WO2006085407A1 (ja) | Hcv量に関連する遺伝子のスクリーニング方法 |